BioSpace News Archive

Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS) today reported financial results and operating highlights for the fourth quarter and full year ended December 31, 2023.

Femasys Inc., a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the year ended December 31, 2023 and provides a corporate update.

Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC) today announced that management will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium, being held on Tuesday, April 2, 2024 at 10:40 a.m. ET.

CervoMed Inc., a clinical stage company focused on developing treatments for age-related neurologic disorders, announced that Company’s Management will participate in the following three investor conferences during the month of April.

ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the full year ended December 31, 2023 and highlighted recent corporate updates and upcoming milestones.

Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) – a commercial-stage medical technology company – today reported financial results for the quarter and year ended December 31, 2023 and provided a corporate update.

Medigene AG reported financial results for the fiscal year ended December 31, 2023, and provided a corporate update.

Intravacc and Primrose Bio announced a strategic partnership to enhance the development and supply of conjugate vaccines.

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces its financial results for the year ended 31 December 2023, and provides a business update and outlook for 2024 and beyond.

Vicore Pharma Holding AB announced multiple presentations at the 2024 American Thoracic Society International Conference, including an oral late-breaking presentation of the final Phase 2a AIR data of buloxibutid in patients suffering from idiopathic pulmonary fibrosis.